| Cell line name |
HRC45 |
|---|
| Synonyms |
HRC-45 |
|---|
| Accession |
CVCL_IS24 |
|---|
| Resource Identification Initiative |
To cite this cell line use: HRC45 (RRID:CVCL_IS24) |
|---|
| Disease |
Clear cell renal cell carcinoma (NCIt: C4033)
Clear cell renal carcinoma (ORDO: Orphanet_319276) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
65Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=21854714; PMCID=PMC3182114
Daniel Canter, Alexander Kutikov, Konstantin Golovine, Petr Makhov, Jay Simhan, Robert G. Uzzo, Vladimir M. Kolenko;
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines.
Can. J. Urol. 18:5819-5825(2011) PubMed=23657944; DOI=10.1158/1535-7163.MCT-12-1010; PMCID=PMC3746800
Roshan Jung Thapa, Pei-Rong Chen, Mitchell Cheung, Shoko Nogusa, Jian-Ming Pei, Suraj Peri, Joseph R. Testa, Siddharth Balachandran;
NF-kappaB inhibition by bortezomib permits IFN-gamma-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
Mol. Cancer Ther. 12:1568-1578(2013) PubMed=27993170; DOI=10.1186/s12943-016-0565-8; PMCID=PMC5168717
Klaudia Klarysa Brodaczewska, Cezary Szczylik, Michal Fiedorowicz, Camillo Porta, Anna Malgorzata Czarnecka;
Choosing the right cell line for renal cell cancer research.
Mol. Cancer 15:83.1-83.15(2016) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54895228
|
|---|
| Entry history |
|---|
| Entry creation | 03-Mar-2017 |
|---|
| Last entry update | 21-Mar-2023 |
|---|
| Version number | 6 |
|---|
